Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Marsh

Showing results (451-460 of 654) with videos related to

Pageof 66
Sort By:
Bioorganic & Medicinal Chemistry|September 1, 1994
Design of orally bioavailable, symmetry-based inhibitors of HIV proteaseD J Kempf, K C Marsh, L C Fino, et al.
Frontiers in Health Services|January 8, 2025
Patient experience of an abstinence-based Indigenous residential treatment program in Northern Ontario: a descriptive qualitative studyT N Marsh, C Eshakakogan, M Spence, et al.
Bone Marrow Transplantation|May 1, 1996
Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donorsM Hamblin, J C Marsh, M Lawler, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 1995
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humansD J Kempf, K C Marsh, J F Denissen, et al.
Journal of Cardiovascular Pharmacology|July 10, 2004
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canineRyan M Fryer, Lee C Preusser, Samuel V Calzadilla, et al.
Cancer Chemotherapy and Pharmacology|June 3, 2004
Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic studyJason A Segreti, James S Polakowski, Kristin A Koch, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1991
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 proteaseD J Kempf, K C Marsh, D A Paul, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 25, 2013
FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcomeShun He, Jianhong Chu, Sumithira Vasu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2017
CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor EfficacyAnna Wasiuk, James Testa, Jeff Weidlick, et al.
Hospital Pediatrics|February 16, 2026
Timing of Renal and Bladder Ultrasound After First Febrile Urinary Tract Infection: A Hospitalist DilemmaMelanie C Marsh, Lauren Abbas, Michael F Perry, et al.
Pageof 66

Showing results (451-460 of 654) with videos related to

Sort By:
Pageof 66
Bioorganic & Medicinal Chemistry|September 1, 1994
Design of orally bioavailable, symmetry-based inhibitors of HIV proteaseD J Kempf, K C Marsh, L C Fino, et al.
Frontiers in Health Services|January 8, 2025
Patient experience of an abstinence-based Indigenous residential treatment program in Northern Ontario: a descriptive qualitative studyT N Marsh, C Eshakakogan, M Spence, et al.
Bone Marrow Transplantation|May 1, 1996
Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donorsM Hamblin, J C Marsh, M Lawler, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 1995
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humansD J Kempf, K C Marsh, J F Denissen, et al.
Journal of Cardiovascular Pharmacology|July 10, 2004
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canineRyan M Fryer, Lee C Preusser, Samuel V Calzadilla, et al.
Cancer Chemotherapy and Pharmacology|June 3, 2004
Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic studyJason A Segreti, James S Polakowski, Kristin A Koch, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1991
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 proteaseD J Kempf, K C Marsh, D A Paul, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 25, 2013
FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcomeShun He, Jianhong Chu, Sumithira Vasu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2017
CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor EfficacyAnna Wasiuk, James Testa, Jeff Weidlick, et al.
Hospital Pediatrics|February 16, 2026
Timing of Renal and Bladder Ultrasound After First Febrile Urinary Tract Infection: A Hospitalist DilemmaMelanie C Marsh, Lauren Abbas, Michael F Perry, et al.
Pageof 66